Deep Med IO
DeepPath is a MedTech company based in the UK and Greece that develops AI-powered diagnostic tools to improve cancer patient care. Their flagship product, DeepPath – LYDIA, is a CE-Marked AI decision support system that detects metastases on digitized microscope slides of H&E stained lymph nodes for breast, lung, colon cancer, and melanoma. LYDIA accelerates diagnosis by up to 5 times with high sensitivity and low false positives, supporting multiple scanner formats and scalable GPU processing. The company offers flexible deployment and licensing models, including cloud, local, standalone software, and PACS integration, targeting histopathologists and cancer diagnostic labs. DeepPath has collaborations with leading medical institutions and has won awards and grants, positioning it as a key player in AI-augmented histopathology.
Deep Med IO
DeepPath is a MedTech company based in the UK and Greece that develops AI-powered diagnostic tools to improve cancer patient care. Their flagship product, DeepPath – LYDIA, is a CE-Marked AI decision support system that detects metastases on digitized microscope slides of H&E stained lymph nodes for breast, lung, colon cancer, and melanoma. LYDIA accelerates diagnosis by up to 5 times with high sensitivity and low false positives, supporting multiple scanner formats and scalable GPU processing. The company offers flexible deployment and licensing models, including cloud, local, standalone software, and PACS integration, targeting histopathologists and cancer diagnostic labs. DeepPath has collaborations with leading medical institutions and has won awards and grants, positioning it as a key player in AI-augmented histopathology.